Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., . . . Richardson, P. G. (2020). Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J.
Stile di citazione ChicagoDimopoulos, Meletios A., et al. "Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results From the Phase 3 Randomized ELOQUENT-2 Study." Blood Cancer J 2020.
Citazione MLADimopoulos, Meletios A., et al. "Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results From the Phase 3 Randomized ELOQUENT-2 Study." Blood Cancer J 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.